Renaissance Technologies LLC Lowers Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Renaissance Technologies LLC lowered its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 20.6% during the 2nd quarter, Holdings Channel reports. The firm owned 173,700 shares of the company’s stock after selling 45,100 shares during the quarter. Renaissance Technologies LLC’s holdings in Centessa Pharmaceuticals were worth $1,569,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Quarry LP bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth $48,000. EntryPoint Capital LLC bought a new position in Centessa Pharmaceuticals during the 1st quarter worth about $109,000. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 69.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after purchasing an additional 4,423 shares during the period. Lynx1 Capital Management LP bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $197,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $330,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Up 0.4 %

Centessa Pharmaceuticals stock opened at $15.94 on Friday. Centessa Pharmaceuticals plc has a one year low of $5.33 and a one year high of $17.59. The stock has a market cap of $1.60 billion, a PE ratio of -11.11 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. The stock has a 50-day moving average of $13.52 and a two-hundred day moving average of $11.00.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.62 EPS for the current fiscal year.

Insider Activity

In related news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the transaction, the chief executive officer now owns 827,755 shares in the company, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Gregory M. Weinhoff sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the sale, the insider now owns 223,369 shares in the company, valued at $3,350,535. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 288,492 shares of company stock valued at $4,641,902 over the last ninety days. 11.59% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CNTA shares. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective on the stock. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Guggenheim raised their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Finally, Jefferies Financial Group raised their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.